Leaders in food-system applications of artificial intelligence say the past year has brought whiplash-inducing transform…

As the biologicals industry continues its rapid global expansion, partnerships are increasingly emerging as one of the sector’s most important growth drivers. During a recent “Biological Expansions: How To Stay Competitive” webinar hosted by AgriBusiness Global, industry experts explored the evolving role of partnerships in helping biological companies scale innovation, access new markets, and remain competitive in a more crowded marketplace.

世界农化网中文网报道：2026年5月20日，中国农药工业协会发布了2025年度农药行业销售额5亿元以上企业名单。

Paris-based Nanobiotix filed the paperwork for the share offering on Wednesday evening and paused trading of its stock Thursday morning. The pause, which is scheduled to lift later on Thursday, is intended to allow Nanobiotix to confirm allocations to investors and announce the pricing of the stock offering. 

By Autumn Demberger, Global AgInvesting MediaAs those from around the world gear up for GAI Australia, Queensland’s Department of Primary Industries has been thinking about how best to bring the area’s investment opportunities centerstage. The June 10-11 event will mark the inaugural summit where Global AgInvesting Australia will bring together institutional investors, fund managers, industry executives, and agtech innovators to explore Australia’s agribusiness opportunities. 

To handle a wide diversity of crops, fields and farming conditions, a mounted telescopic planter must be able to combine excellent planting precision with the highest level of versatility. “When designing the next generation Tempo T, we put extra focus on one main thing: the telescopic function. We developed a robust frame, a clean and simple design, excellent accessibility and above all, simple and fast row spacing adjustment. Row spacing is now adjusted easily with a single handle, all rows at the same time.”, says Oskar Karlsson, Vice President Product & Development Planters, at Väderstad, and

AgFunderNews rounds up the most important fundings, mergers, acquisitions, closures, and industry buzz in agtech and foo…

UK-based Infex Therapeutics has reported positive Phase IIa data for RESP-X, its first-in-class anti-virulence monoclonal antibody for non-cystic fibrosis bronchiectasis patients colonised with Pseudomonas aeruginosa . The randomised, double-blind, placebo-controlled dose-ranging trial met its primary objective, showing that RESP-X was safe and well tolerated in this high-risk patient group. The study also met secondary objectives, with favourable pharmacokinetics, no detected immunogenicity and lung deposition supporting a potential quarterly dosing schedule.